Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 7/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.65 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.65 |
| ▸ | ADA | P00813 | 1/20 | 0.62 |
| ▸ | PI4KA | P42356 | 2/20 | 0.61 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.61 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.61 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.61 |
| ▸ | DPP4 | P27487 | 1/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.61 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.61 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.61 |
| ▸ | GAPDH | P04406 | 1/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
| ▸ | STAT6 | P42226 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12154700 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL19402567 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL18561529 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL14842184 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL24837583 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL12300485 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL24838594 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL21006596 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL21081913 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADA | |
| SCHEMBL13559230 | 1.00 | ADORA2A (1.00) | ADORA2AADORA3ADORA1ADORA2BADA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062181-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2023-03-02 | — | — | US | disclosed |
| US-11192914-B2 | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto | EMORY UNIVERSITY (US) | 2021-12-07 | — | — | US | disclosed |
| US-20190144484-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY | 2019-05-16 | — | — | US | disclosed |
| WO-2017189978-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2017-11-02 | — | — | WO | disclosed |
| US-9365604-B2 | Oligomer-nucleoside phosphate conjugates | NEKTAR THERAPEUTICS (US) | 2016-06-14 | — | — | US | disclosed |
| US-9186369-B2 | Purine nucleoside analogues for treating flaviviridae including hepatitis C | IDENIX PHARMACEUTICALS, LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150266918-A1 | Bridged-Cyclo-ProTides as Prodrugs of Therapeutic Nucleosides and Nucleotides | ZHONG MINGHONG (US) | 2015-09-24 | — | — | US | disclosed |
| US-8871785-B2 | Antiviral phosphonate analogs | GILEAD SCIENCES, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140234251-A1 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING FLAVIVIRIDAE INCLUDING HEPATITIS C | INDENIX PHARMACEUTICALS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-8741858-B2 | Oligomer-nucleoside phosphate conjugates | NEKTAR THERAPEUTICS | 2014-06-03 | — | — | US | disclosed |
| US-8742101-B2 | Purine nucleoside analogues for treating flaviviridae including hepatitis C | IDENIX PHARMACEUTICALS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8658616-B2 | Nucleoside aryl phosphoramidates and their use as anti-viral agents for the treatment of hepatitis C virus | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2014-02-25 | — | — | US | disclosed |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-24 | — | — | US | disclosed |
| US-20110124592-A1 | NUCLEOSIDE ARYL PHOSPHORAMIDATES AND THEIR USE AS ANTI-VIRAL AGENTS FOR THE TREATMENT OF HEPATITUS C VIRUS | K.U. LEUVEN RESEARCH AND DEVELOPMENT (BE) | 2011-05-26 | — | — | US | disclosed |
| US-20100286084-A1 | Oligomer-Nucleoside Phosphate Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | disclosed |
| US-20090169507-A1 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING FLAVIVIRIDAE INCLUDING HEPATITIS C | IDENIX PHARMACEUTICALS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192914-B2 | Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto | PNP, NTPCR, TYMP | ADORA2A 76/4885ADORA3 69/4885ADORA1 73/4885 |
| US-20110288053-A1 | ANTIVIRAL PHOSPHONATE ANALOGS | TYMP, ITPA, PNP | ADORA2A 1057/4885ADORA3 936/4885ADORA1 1306/4885 |
| US-20110124592-A1 | NUCLEOSIDE ARYL PHOSPHORAMIDATES AND THEIR USE AS ANTI-VIRAL AGENTS FOR THE TREATMENT OF HEPATITUS C VIRUS | PNP, NSUN2, MTAP | ADORA2A 292/4885ADORA3 113/4885ADORA1 152/4885 |
| US-20140234251-A1 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING FLAVIVIRIDAE INCLUDING HEPATITIS C | PNP, TPMT, MTAP | ADORA2A 112/4885ADORA3 236/4885ADORA1 297/4885 |
| US-20090169507-A1 | PURINE NUCLEOSIDE ANALOGUES FOR TREATING FLAVIVIRIDAE INCLUDING HEPATITIS C | PNP, TPMT, MTAP | ADORA2A 112/4885ADORA3 236/4885ADORA1 297/4885 |
| US-20190144484-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | TYMP, PNP, NTPCR | ADORA2A 83/4885ADORA3 80/4885ADORA1 108/4885 |
| US-20150266918-A1 | Bridged-Cyclo-ProTides as Prodrugs of Therapeutic Nucleosides and Nucleotides | TYMP, ENPP3, PNP | ADORA2A 55/4885ADORA3 18/4885ADORA1 215/4885 |
| US-20100286084-A1 | Oligomer-Nucleoside Phosphate Conjugates | ENTPD5, SLC29A2, SLC29A1 | ADORA2A 93/4885ADORA3 62/4885ADORA1 115/4885 |
| US-20230062181-A1 | ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | TYMP, NTPCR, PNP | ADORA2A 93/4885ADORA3 82/4885ADORA1 126/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.